Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |